TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mindfulness Based Relapse Prevention: Efficacy and Mechanisms
Brief Summary: The broad, long-term objective of the proposed randomized clinical trial is to evaluate the efficacy, moderators and mechanisms of change of two cognitive-behavioral aftercare treatments for alcohol and other drug (AOD) use disorders in preventing AOD relapse compared to treatment as usual (TAU) offered in the community. The two cognitive-behavioral aftercare treatments are relapse prevention (RP) and Mindfulness-Based Relapse Prevention (MBRP), which integrates mindfulness meditation and RP aftercare components.


Options:
A: Arm Label: MBRP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness Based Relapse Prevention | Arm Label: Relapse Prevention (RP); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Relapse Prevention | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Relapse Prevention; Assigned to Arm(s): MBRP | Intervention Type: BEHAVIORAL; Name: Relapse Prevention; Assigned to Arm(s): Relapse Prevention (RP) | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual
B: Arm Label: Mindfulness-Oriented Recovery Enhancement; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-Oriented Recovery Enhancement | Arm Label: Supportive Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Counseling | Intervention Type: BEHAVIORAL; Name: Mindfulness-Oriented Recovery Enhancement; Assigned to Arm(s): Mindfulness-Oriented Recovery Enhancement | Intervention Type: BEHAVIORAL; Name: Supportive Counseling; Assigned to Arm(s): Supportive Counseling
C: Arm Label: IIDEA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Integrated Intervention for Dual Problems and Early Action | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrated Intervention for Dual Problems and Early Action; Assigned to Arm(s): IIDEA
D: Arm Label: Mindfulness Training for Smokers; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness Training for Smokers | Arm Label: Interactive Learning for Smokers; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interactive Learning for Smokers | Intervention Type: BEHAVIORAL; Name: Mindfulness Training for Smokers; Assigned to Arm(s): Mindfulness Training for Smokers | Intervention Type: BEHAVIORAL; Name: Interactive Learning for Smokers; Assigned to Arm(s): Interactive Learning for Smokers

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A. POTTER
Brief Summary: The project is a controlled observational, multicenter, prospective data collection on secondary prophylaxis with Kogenate Bayer in adolescents and adults with severe haemophilia A (FVIII \< 1%).

The observational period will cover at least 5 years per patient.

The long-term secondary prophylaxis group will be compared versus on-demand treatment group by the assessment of orthopedic status progression and pharmacoeconomics evaluation.


Options:
A: Arm Label: Group 1; Type: N/A; Interventions: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222) | Arm Label: Group 2; Type: N/A; Interventions: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222) | Intervention Type: DRUG; Name: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Recombinant Factor VIII (Kogenate FS, BAY14-2222); Assigned to Arm(s): Group 2
B: Arm Label: Concizumab; Type: EXPERIMENTAL; Interventions: Drug: Concizumab, Drug: Eptacog alfa | Arm Label: Eptacog alfa and concizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concizumab, Drug: Eptacog alfa | Intervention Type: DRUG; Name: Concizumab; Assigned to Arm(s): Concizumab, Eptacog alfa and concizumab | Intervention Type: DRUG; Name: Eptacog alfa; Assigned to Arm(s): Concizumab, Eptacog alfa and concizumab
C: Arm Label: All participants; Type: EXPERIMENTAL; Interventions: Drug: BIIB031 (rFVIIIFc), Drug: FVIII (PK subgroup only) | Intervention Type: DRUG; Name: BIIB031 (rFVIIIFc); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: FVIII (PK subgroup only); Assigned to Arm(s): All participants
D: Arm Label: Concizumab; Type: EXPERIMENTAL; Interventions: Drug: Concizumab, Drug: placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Concizumab; Assigned to Arm(s): Concizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Concizumab, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Southern Ethiopia: a Cluster-randomized Controlled Trial
Brief Summary: The combined use of a mosquito repellent and long lasting insecticidal nets (LLINs) by household members would result in a 40% reduction in malaria prevalence compared with households that only use LLINs.


Options:
A: Intervention Type: DEVICE; Name: Insect Repellent plus Insecticide Treated Net; Assigned to Arm(s): N/A
B: Arm Label: 20% deet insect repellent; Type: EXPERIMENTAL; Interventions: Drug: 20% deet insect repellent | Arm Label: lotion without repellent active; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo control | Intervention Type: DRUG; Name: 20% deet insect repellent; Assigned to Arm(s): 20% deet insect repellent | Intervention Type: DRUG; Name: placebo control; Assigned to Arm(s): lotion without repellent active
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo lotion, Other: Army combat uniform | Arm Label: Combo; Type: ACTIVE_COMPARATOR; Interventions: Other: Ultra 30 Insect Repellent Lotion (30% Lipo DEET), Other: Permethrin Factory-Treated Army Combat Uniforms | Arm Label: Permethrin; Type: ACTIVE_COMPARATOR; Interventions: Other: Permethrin Factory-Treated Army Combat Uniforms, Other: Placebo lotion | Arm Label: DEET; Type: ACTIVE_COMPARATOR; Interventions: Other: Ultra 30 Insect Repellent Lotion (30% Lipo DEET), Other: Army combat uniform | Intervention Type: OTHER; Name: Ultra 30 Insect Repellent Lotion (30% Lipo DEET); Assigned to Arm(s): Combo, DEET | Intervention Type: OTHER; Name: Permethrin Factory-Treated Army Combat Uniforms; Assigned to Arm(s): Combo, Permethrin | Intervention Type: OTHER; Name: Placebo lotion; Assigned to Arm(s): Permethrin, Placebo | Intervention Type: OTHER; Name: Army combat uniform; Assigned to Arm(s): DEET, Placebo
D: Arm Label: Mosquito repellent and LLINs group vs. LLINs group only; Type: EXPERIMENTAL; Interventions: Other: Mosquito repellent | Intervention Type: OTHER; Name: Mosquito repellent; Assigned to Arm(s): Mosquito repellent and LLINs group vs. LLINs group only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Southern Ethiopia: a Cluster-randomized Controlled Trial
Brief Summary: The combined use of a mosquito repellent and long lasting insecticidal nets (LLINs) by household members would result in a 40% reduction in malaria prevalence compared with households that only use LLINs.


Options:
A: Arm Label: Mosquito repellent and LLINs group vs. LLINs group only; Type: EXPERIMENTAL; Interventions: Other: Mosquito repellent | Intervention Type: OTHER; Name: Mosquito repellent; Assigned to Arm(s): Mosquito repellent and LLINs group vs. LLINs group only
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: LLIN | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Device: mosquito coils | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Device: mosquito coils | Intervention Type: DEVICE; Name: mosquito coils; Assigned to Arm(s): 3, 4 | Intervention Type: DEVICE; Name: LLIN; Assigned to Arm(s): 2
C: Arm Label: Topical Repellent & LLIN; Type: EXPERIMENTAL; Interventions: Other: Mosquito topical repellent | Arm Label: Long Lasting Insecticidal Nets; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mosquito topical repellent; Assigned to Arm(s): Topical Repellent & LLIN
D: Arm Label: 20% deet insect repellent; Type: EXPERIMENTAL; Interventions: Drug: 20% deet insect repellent | Arm Label: lotion without repellent active; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo control | Intervention Type: DRUG; Name: 20% deet insect repellent; Assigned to Arm(s): 20% deet insect repellent | Intervention Type: DRUG; Name: placebo control; Assigned to Arm(s): lotion without repellent active

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis
Brief Summary: This is a Phase Ib, randomized, blinded, placebo-controlled, multiple-ascending dose study in patients with seasonal or perennial allergic rhinitis to investigate the safety, tolerability, and pharmacokinetics (PK) of MEMP1972A.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A, B, C
B: Arm Label: Placebo (for Dupilumab); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Dupilumab), Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Fluticasone/Salmeterol combination therapy, Drug: Fluticasone monotherapy, Drug: Albuterol, Drug: Levalbuterol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone/Salmeterol combination therapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Fluticasone monotherapy; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Levalbuterol; Assigned to Arm(s): Dupilumab 300 mg qw, Placebo (for Dupilumab)
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: IMA-026 | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: IMA-026; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: 1; Type: OTHER; Interventions: Biological: IMA-638 is a biologic | Intervention Type: BIOLOGICAL; Name: IMA-638 is a biologic; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis
Brief Summary: This is a Phase Ib, randomized, blinded, placebo-controlled, multiple-ascending dose study in patients with seasonal or perennial allergic rhinitis to investigate the safety, tolerability, and pharmacokinetics (PK) of MEMP1972A.


Options:
A: Arm Label: huMAb OX40L; Type: EXPERIMENTAL; Interventions: Drug: huMAb OX40L | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: huMAb OX40L; Assigned to Arm(s): huMAb OX40L | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MEDI-563 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MEDI-563 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Comp. | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: MEDI-563; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: MEDI-563; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Placebo Comp.; Assigned to Arm(s): 4 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 5
C: Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A, B, C

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single to Multi-Dose Study of Safety, Tolerability, and Bioeffect of Subcutaneously Administered REGN727 in Patients With and Without Concomitant Atorvastatin
Brief Summary: This study will test the safety, tolerability, and bioeffects (how the body reacts to the drug) of REGN727 compared with placebo (an inactive substance that contains no medicine) in hyperlipidemic patients with or without atorvastatin therapy. The study drug and placebo will be administered by subcutaneous injection at the clinic. There will be a total of 2 or 3 study drug injections over 16 clinic visits, which will include 3 overnight stays(study duration 148 days, not including the screening period). Patients on atorvastatin will take their daily dose in the morning for the duration of the study. Patients will be monitored by the study staff for side effects and the body's response to the study drug. Vital signs(blood pressure, temperature, breathing and heart rate) will be checked, and blood and urine samples will be collected at some or all visits.


Options:
A: Arm Label: atorvastatin 10 mg, 80 mg; Type: EXPERIMENTAL; Interventions: Drug: statin | Intervention Type: DRUG; Name: statin; Assigned to Arm(s): atorvastatin 10 mg, 80 mg
B: Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
C: Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Lipitor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lipitor; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group 1 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 2 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 3 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 4 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 5 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 6 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 7 without atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 8 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Intervention Type: DRUG; Name: REGN727(SAR236553); Assigned to Arm(s): Group 1 with atorvastatin, Group 2 with atorvastatin, Group 3 with atorvastatin, Group 4 with atorvastatin, Group 5 with atorvastatin, Group 6 with atorvastatin, Group 7 without atorvastatin, Group 8 with atorvastatin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Peer-Assisted Asthma Self-Management Program for Adolescents
Brief Summary: Aims of this study are:

1. To determine the feasibility of implementing the intervention using a peer-assisted asthma day camp for adolescents with asthma.
2. To determine patterns of change in knowledge, attitudes toward asthma, self-efficacy, perception of barriers, and self-management behaviors, asthma control and quality of life over time among peer leaders.
3. To test the following hypothesis:

   * Adolescents participating in a peer-assisted asthma camp program will report improved knowledge, attitudes toward asthma, self-efficacy, and self-management behaviors, decreased perception of barriers, and increased asthma control and quality of life at 3-, 6- and 9-months post-intervention compared with the adult-led camp group.
4. To examine the moderating effect of personal factors (e.g., age, sex, socioeconomic status, race, illness status, family support) on intervention outcomes such as self-management behaviors, asthma control and quality of life in adolescents with asthma.
5. To examine the effect of the peer-assisted camp program on self-reported health care utilization including emergency department visits, days of hospitalization, outpatient visits by comparing between baseline and 9-months post-camp data and between the peer-led camp and the adult-camp programs.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: School-based Care; Type: EXPERIMENTAL; Interventions: Behavioral: School-based Care | Intervention Type: BEHAVIORAL; Name: School-based Care; Assigned to Arm(s): School-based Care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: School-Based Supervised Asthma Therapy | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: School-Based Supervised Asthma Therapy; Assigned to Arm(s): 1
C: Arm Label: peer-led asthma self-managment program; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-assisted asthma self-management program | Arm Label: Adult-led asthma self-management program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adult-led asthma self-management program | Intervention Type: BEHAVIORAL; Name: Peer-assisted asthma self-management program; Assigned to Arm(s): peer-led asthma self-managment program | Intervention Type: BEHAVIORAL; Name: Adult-led asthma self-management program; Assigned to Arm(s): Adult-led asthma self-management program
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: School-based Care; Type: EXPERIMENTAL; Interventions: Behavioral: School-based Care | Intervention Type: BEHAVIORAL; Name: School-based Care; Assigned to Arm(s): School-based Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Peer-Assisted Asthma Self-Management Program for Adolescents
Brief Summary: Aims of this study are:

1. To determine the feasibility of implementing the intervention using a peer-assisted asthma day camp for adolescents with asthma.
2. To determine patterns of change in knowledge, attitudes toward asthma, self-efficacy, perception of barriers, and self-management behaviors, asthma control and quality of life over time among peer leaders.
3. To test the following hypothesis:

   * Adolescents participating in a peer-assisted asthma camp program will report improved knowledge, attitudes toward asthma, self-efficacy, and self-management behaviors, decreased perception of barriers, and increased asthma control and quality of life at 3-, 6- and 9-months post-intervention compared with the adult-led camp group.
4. To examine the moderating effect of personal factors (e.g., age, sex, socioeconomic status, race, illness status, family support) on intervention outcomes such as self-management behaviors, asthma control and quality of life in adolescents with asthma.
5. To examine the effect of the peer-assisted camp program on self-reported health care utilization including emergency department visits, days of hospitalization, outpatient visits by comparing between baseline and 9-months post-camp data and between the peer-led camp and the adult-camp programs.


Options:
A: Arm Label: peer-led asthma self-managment program; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-assisted asthma self-management program | Arm Label: Adult-led asthma self-management program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adult-led asthma self-management program | Intervention Type: BEHAVIORAL; Name: Peer-assisted asthma self-management program; Assigned to Arm(s): peer-led asthma self-managment program | Intervention Type: BEHAVIORAL; Name: Adult-led asthma self-management program; Assigned to Arm(s): Adult-led asthma self-management program
B: Arm Label: community health worker; Type: EXPERIMENTAL; Interventions: Behavioral: community health worker | Arm Label: mailed information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: mailed information | Intervention Type: BEHAVIORAL; Name: community health worker; Assigned to Arm(s): community health worker | Intervention Type: BEHAVIORAL; Name: mailed information; Assigned to Arm(s): mailed information
C: Arm Label: Nurse group; Type: EXPERIMENTAL; Interventions: Behavioral: Self management education | Arm Label: Lay educator group; Type: EXPERIMENTAL; Interventions: Behavioral: Self management education | Intervention Type: BEHAVIORAL; Name: Self management education; Assigned to Arm(s): Lay educator group, Nurse group
D: Intervention Type: DEVICE; Name: electronic medication monitoring system; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: parent-adolescent communication and problem-solving skills; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease
Brief Summary: The purpose of this study is to gain a better understanding of calcium absorption and metabolism in patients with Chronic Kidney Disease (CKD) using calcium balance and kinetic methods.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer carbonate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sevelamer carbonate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: calcium acetate, Drug: atorvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: sevelamer, Drug: atorvastatin | Intervention Type: DRUG; Name: calcium acetate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sevelamer; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): 1, 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Calcium Carbonate (Phosphate Binder); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 1500 mg/d elemental calcium as calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: 1500 mg/d elemental calcium as calcium carbonate; Assigned to Arm(s): Calcium Carbonate (Phosphate Binder) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Lanthanum carbonate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lanthanum carbonate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C